XEN®-45 implantation for refractory uveitic glaucoma
Authors:
Open Access
- 19 October 2023
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 262 (3) , 937-948
Abstract
Purpose: To evaluate the efficacy of XEN®-45 gel stent ab interno implantation for medically uncontrolled uveitic glaucoma. Methods: Retrospective analysis of 25 eyes receiving XEN® gel stent for medically uncontrolled uveitic glaucoma from February 2019 to February 2023 with recording of intraocular pressure (IOP) values, ocular hypotensive medication, requirement for revision or secondary surgery and complications. Prerequisites for XEN® implantation were a clear cornea, an open iridocorneal angle and an unscarred, mobile conjunctiva at the implantation site. Minimum follow-up required for inclusion was 3 months. The primary outcome measure was IOP compared to baseline. Complete and qualified success were defined as final IOP of ≤ 18 mmHg without or with topical antiglaucomatous treatment, respectively. Failure was defined as IOP > 18 mmHg on two consecutive visits, IOP reduction < 20%, persisting complications from hypotony and open conjunctival bleb revision. Further glaucoma surgical intervention was defined as complete failure. Results: Mean preoperative IOP was 35.3 ± 10.9 mmHg on 2.9 ± 0.9 topical antiglaucomatous agents. 19 of 25 patients (76%) received additional oral acetazolamide. 19 eyes were pseudophakic, 5 eyes phakic and 1 aphakic. Early postoperatively, mean IOP reduced to 7.7 ± 3.0 mmHg (75.8% reduction). At final follow-up (mean 17.7 months) mean IOP was 12.0 ± 3.8 mmHg (62.5% reduction) on 0.2 ± 0.6 medications. Six eyes (24%) required bleb revision at mean 28 weeks and therefore were categorized as failure. One eye failed despite bleb revision and restart of topical ocular hypotensive medication. Three other eyes (12%) had IOP spikes with uveitis flare-ups. Transient hypotony complications occurred in 32%. At final follow-up, 18 eyes (72%) achieved complete success and one eye (4%) qualified success. Conclusion: The XEN® gel stent effectively reduced IOP in uncontrolled uveitic glaucoma, with 72% complete success. Bleb revision was required in 24%. IOP spikes occurred in 12% despite functioning blebs. Further follow-up is needed to determine long-term outcomes.Keywords
Funding Information
- Universitätsklinikum Freiburg
This publication has 36 references indexed in Scilit:
- XEN‐45 collagen implant for the treatment of uveitic glaucomaClinical & Experimental Ophthalmology, 2017
- Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone TrabeculectomyOphthalmology, 2017
- One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative managementEye, 2017
- XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and ComplicationsJournal of Ophthalmology, 2017
- Trabeculectomy ab interno with the Trabectome® as a therapeutic option for uveitic secondary glaucomaGraefe's Archive for Clinical and Experimental Ophthalmology, 2015
- Trabeculectomy ab interno (trabectome): yet another possibility in the treatment of uncontrolled glaucomatocyclitic crisis under systemic valganciclovir therapy?Eye, 2015
- Ab interno approach to the subconjunctival space using a collagen glaucoma stentJournal of Cataract & Refractive Surgery, 2014
- Trabeculectomy with Antiproliferative Agents in Uveitic GlaucomaJournal of Glaucoma, 2002
- Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucomaOphthalmology, 2000
- Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitisAmerican Journal of Ophthalmology, 1999